T-20 blocker of viral fusion to cells: TRMS begin phase II trial in up to 78 HIV-infected patients assess optimal dosing.

Trimeris Inc. (TRMS), Durham, N.C.
Product:

Read the full 67 word article

How to gain access

Continue reading with a
two-week free trial.